10-Q quarterly report · filed Nov 9, 2026

OCULAR THERAPEUTIX, INC (OCUL) Q3 2026 10-Q Quarterly Report

Short answer

OCULAR THERAPEUTIX, INC (OCUL) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M (down 11.5% year over year) with net income of −$95M.

Q3 2026 key financials · XBRL

Revenue
$13M
−11.5% YoY · −4.5% QoQ
Net income
−$95M
−36.5% YoY · −20.3% QoQ
Operating margin
-760.1%
EPS (diluted)
−$0.42
−10.5% YoY · −20.0% QoQ

Source: XBRL data from the OCULAR THERAPEUTIX, INC (OCUL) Q3 2026 10-Q on SEC EDGAR. USD.

OCULAR THERAPEUTIX, INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $12.9M, down 11.0% YoY from $14.5M, entirely DEXTENZA product revenue
  • Net loss $94.8M vs $69.4M YoY, operating loss $97.9M vs $68.7M
  • Worst performer DEXTENZA: revenue down $1.6M, GTN provisions 57.7% vs 52.5%
  • Cash and equivalents $530.6M, operating cash use $198.9M for nine months vs $150.6M YoY
  • Outlook: NDA submission targeted Q4 2026, cash expected to fund operations into 2028, R&D expenses expected to increase

Risk Factors

  • No material risk-factor changes disclosed from the December 31, 2025 Form 10-K
  • Clinical-development risk: AXPAXLI direct program expenses rose to $119,966 through nine months
  • Legal risk: EyePoint litigation settled October 30, 2026 with no financial obligation
  • Liquidity risk: $530,612 cash supports planned operations through 12 months while maintaining $20,000 minimum liquidity
  • Debt risk: $82,474 Barings principal due in 2029 with SOFR plus 6.75% interest terms

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other OCULAR THERAPEUTIX, INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.